| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/11/2010 | US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors |
| 02/11/2010 | US20100035936 Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands |
| 02/11/2010 | US20100035929 Unnatural dispyrin analogues, preparation and uses thereof |
| 02/11/2010 | US20100035916 Azabicycloalkane derivatives, preparation thereof and use thereof in therapy |
| 02/11/2010 | US20100035906 Dipyridyl-dihydropyrazolones and their use |
| 02/11/2010 | US20100035902 5-aryl-substituted dihydropyridopyrimidines and dihydropyridazines and use thereof as mineral corticoid antagonists |
| 02/11/2010 | US20100035899 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY |
| 02/11/2010 | US20100035895 2-aminocarbonyl-pyridine derivatives |
| 02/11/2010 | US20100035893 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 02/11/2010 | US20100035891 Pharmaceutically Active Compounds |
| 02/11/2010 | US20100035890 Use of ranolazine for the treatment of cardiovascular diseases |
| 02/11/2010 | US20100035889 Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure |
| 02/11/2010 | US20100035885 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 02/11/2010 | US20100035882 Inhibition of pde2a |
| 02/11/2010 | US20100035875 Triazolopyridine jak inhibitor compounds and methods |
| 02/11/2010 | US20100035865 Sulfonamides and Pharmaceutical Compositions Thereof |
| 02/11/2010 | US20100035860 Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy |
| 02/11/2010 | US20100035849 Novel methylenedioxy phenolic compounds and their use to treat disease |
| 02/11/2010 | US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 02/11/2010 | US20100035827 Multivalent metal salts of boronic acids |
| 02/11/2010 | US20100035821 Amide Linkage Cyclic Natriuretic Peptide Constructs |
| 02/11/2010 | US20100034867 Drug delivery coating for use with a medical device and methods of treating vascular injury |
| 02/11/2010 | US20100034823 Crystalline anti-hTNFalpha antibodies |
| 02/11/2010 | US20100034804 Mutants of streptokinase and their covalently modified forms |
| 02/11/2010 | CA2733430A1 Novel methylenedioxy phenolic compounds and their use to treat disease |
| 02/11/2010 | CA2733149A1 Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack |
| 02/11/2010 | CA2732797A1 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 02/11/2010 | CA2732785A1 Compounds and methods |
| 02/11/2010 | CA2732762A1 Urotensin ii receptor antagonists |
| 02/11/2010 | CA2732071A1 Long-term treatment of symptomatic heart failure |
| 02/11/2010 | CA2731095A1 Compounds useful as inhibitors of protein kinases |
| 02/10/2010 | EP2151454A2 Platelet-derived growth factor D, DNA coding therefor, and uses thereof |
| 02/10/2010 | EP2151439A1 Nitrogenated aromatic 6-membered ring derivative, and pharmaceutical agent comprising the same |
| 02/10/2010 | EP2151436A1 Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity |
| 02/10/2010 | EP2150547A2 Polymorphic forms of bosentan |
| 02/10/2010 | EP2150260A2 Compositions and methods for the treatment of heart failure |
| 02/10/2010 | EP2150251A1 Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| 02/10/2010 | EP2150117A1 Methods and compositions for mitochondrial replacement therapy |
| 02/10/2010 | EP1701951B1 Modulators of peripheral 5-ht receptors |
| 02/10/2010 | EP1525191B1 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 02/10/2010 | EP1490365B1 Azaindoles as inhibitors of c-jun n-terminal kinases |
| 02/10/2010 | EP1411932B1 Substituted oxazolidinones for combinational therapy |
| 02/10/2010 | CN101642459A Combination dosage form containing a cholesterol -lowering agent, an inhibitor of the renin-angiotensin, and aspirin |
| 02/10/2010 | CN100588647C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/10/2010 | CN100588398C Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances |
| 02/10/2010 | CN100588396C Composition and methods for treatment of hyperplasia |
| 02/09/2010 | US7659407 Pharmaceutical compounds |
| 02/09/2010 | US7659370 Nervous system protein for use in treatment and prevention of nervous system and seizure disorders |
| 02/09/2010 | US7659293 α-Amino-N-hydroxy-acetamide derivatives |
| 02/09/2010 | US7659282 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 02/09/2010 | US7659272 N-[phenyl or heteroaryl carbonoyl pyridyl] arylsulfonamides; antiinflammatory, antianaphylactic agents; transplant rejection, gastointestinal, respriatory system and skin disorders |
| 02/09/2010 | US7659267 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding |
| 02/09/2010 | US7659249 Membrane-permeable NFAT inhibitory peptide |
| 02/09/2010 | US7658934 Chlamydia antigens and protein vaccine |
| 02/09/2010 | US7658915 Selected cell delivery for heart failure |
| 02/09/2010 | CA2557576C Novel benzothiazepine and benzothiepine compounds |
| 02/09/2010 | CA2484954C 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors |
| 02/09/2010 | CA2451562C Piperazine compound |
| 02/09/2010 | CA2451240C Cyclic diamine compound with 6 membered ring groups |
| 02/09/2010 | CA2440760C Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 02/09/2010 | CA2440588C Chronotherapeutic dosage forms |
| 02/09/2010 | CA2439593C Heterocyclic compounds for aging-related and diabetic vascular complications |
| 02/09/2010 | CA2430273C Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them |
| 02/09/2010 | CA2418224C Pharmaceutical composition |
| 02/09/2010 | CA2413061C Serine protease inhibitors |
| 02/09/2010 | CA2410647C Substituted phenylpropanoic acid derivatives |
| 02/09/2010 | CA2386297C Bicyclic amino acids as pharmaceutical agents |
| 02/09/2010 | CA2378431C Peptides that lower blood glucose levels |
| 02/09/2010 | CA2354762C Novel therapeutic application of low molecular weight heparin |
| 02/09/2010 | CA2274201C Di-or triaza-spiro[4,5]decane derivatives |
| 02/09/2010 | CA2192092C Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors |
| 02/04/2010 | WO2010014933A2 Psma-binding agents and uses thereof |
| 02/04/2010 | WO2010014516A1 Nitro derivatives of furasemide and their use as diuretics |
| 02/04/2010 | WO2010014263A1 Methods and compositions involving (s)-bucindolol |
| 02/04/2010 | WO2010014199A2 Uses of morelloflavone |
| 02/04/2010 | WO2010013978A2 Composition for prevention or treatment of hyperlipidemia, fatty liver or obesity |
| 02/04/2010 | WO2010013595A1 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| 02/04/2010 | WO2010013551A1 Preparation for oral administration comprising water-extracted chondroitin sulfate and quercetin glycoside |
| 02/04/2010 | WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof |
| 02/04/2010 | WO2010013144A2 Antihypertensive composition containing an extract of hymenocardia acida |
| 02/04/2010 | WO2010012817A2 5ht7 receptor ligands and compositions comprising the same |
| 02/04/2010 | WO2010012619A1 Diazepan and piperazine derivatives modulators of chemokine receptors |
| 02/04/2010 | WO2010012611A1 Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it |
| 02/04/2010 | WO2010012438A2 Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor |
| 02/04/2010 | WO2010012399A1 Indolylamides as modulators of the ep<sb>2</sb> receptor |
| 02/04/2010 | WO2010012127A1 Use of a traditional chinese medicinal composition for preparing medicine for promoting bone marrow-derived mesenchymal stem cell survival in vivo and cardiac muscle differentiation |
| 02/04/2010 | WO2010012037A1 6-substituted isoflavonoid compounds and uses thereof |
| 02/04/2010 | WO2009019260A3 Use of tlr-2 antagonists for treatment of reperfusion injury and tissue damage |
| 02/04/2010 | WO2008132710A3 Pharmaceutical nimodipine compositions |
| 02/04/2010 | WO2008121859A8 Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions |
| 02/04/2010 | US20100029922 Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes |
| 02/04/2010 | US20100029919 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| 02/04/2010 | US20100029775 Renin inhibitors for the prevention and treatment of hypertension in obese patients |
| 02/04/2010 | US20100029766 Blends Comprising a Substituted Fatty Acid or a Derivative Thereof |
| 02/04/2010 | US20100029758 Derivatives of isoflavones |
| 02/04/2010 | US20100029756 Novel compositions containing isolated tetrameric type a proanthocyanadin and methods of use and manufacture |
| 02/04/2010 | US20100029743 Atorvastatin pharmaceutical compositions |
| 02/04/2010 | US20100029739 Use of a combination of hypothermia inducing drugs |
| 02/04/2010 | US20100029731 Method for preparing largazole analogs and uses thereof |
| 02/04/2010 | US20100029722 Organic compounds |